Posted by Michael Wonder on 25 Jun 2024
Roche’s Ocrevus subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
25 June 2024 - Roche is working closely with national health systems in Europe to ensure people with multiple sclerosis can access Ocfevus SC as quickly as possible.
Roche announced today that the European Commission has granted marketing authorisation for Ocrevus (ocrelizumab) subcutaneous for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.
